Chiasma Inc. has successfully completed a Phase I clinical trial of its oral Octreolin for the treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone. The safety and pharmacokinetics study found that oral Octreolin had a similar profile to the injected form of the drug, and there were no serious side effects.
Chiasma has submitted an Orphan Drug application to the US FDA for acromegaly and will shortly submit an Orphan Medicinal Product Designation application to the European Medicines Agency (EMEA).
Chiasma plans to begin a pivotal trial of Octreolin by the end of the year. The company estimates that 20,000-30,000 people suffer from acromegaly in the US and Europe.
Chiasma is also developing Octreolin for the treatment of chronic portal hypertension, and plans to begin a clinical trial in December 2010.
According to IVC, Jerusalem-based Chiasma has raised $25.9 million to date from Ofer Hi Tech Ltd., Jerusalem Global Ventures (JGV), MPM Capital, F2 Ventures, and ARCH Venture Partners.
Published by Globes [online], Israel business news - www.globes-online.com - on June 14, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010